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Sphingosine-1-phosphate (S1P) is a lysophospholipid growth factor circulating in blood, 
which induces a wide variety of biological responses in diverse cell types. S1P is 
present at 10-7 M order of concentration in the blood largely in a form bound to plasma 
proteins including albumin and lipoproteins, and released by activated platelets and 
other cell types [1]. Identification of cell surface receptors for S1P provided strong 
support for the notion that many, if not all, of the diversity of biological activities of S1P 
are mediated through either of these receptors [2-5]. Among 5 S1P receptor subtypes, 
S1P1 /Edg (for endothelial differentiation gene)-1, S1P2 /Edg5, S1P3 /Edg3, are widely 
expressed in various tissues [2-5].    
  Cell migration is a critical component of cellular responses, which is involved in such 
diverse physiological and pathological processes as embryonic morphogenesis, 
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angiogenesis, wound healing, atherogenesis, inflammation and tumor cell dissemination 
[6]. Cell migration is regulated in both positive and negative directions by a variety of 
extracellular cues called chemoattractants and chemorepellants, respectively. A number 
of biologically active substances, including chemokines, cytokines and growth factors, 
have been demonstrated to act as chemoattractants to induce chemotaxis, i.e. cell 
migration directed toward a higher concentration of a chemoattractant. Certain factors 
including some members of the semaphorine and the ephrine families were shown to 
directly repel neuronal and vascular cells as chemorepellants. However, our knowledge 
about chemorepellants or migration-inhibitory substances is generally much limited at 
present, compared to chemoattractants [6]. 
  More than 10 years ago, Igarashi and his colleagues demonstrated for the first time 
that S1P exerted inhibitory effects on migration and invasion of certain tumor cells 
including melanoma cells and osteosarcoma cells [7]. They also showed that S1P 
inhibited migration of vascular smooth muscle cells (VSMCs) [8] and neutrophils [9] 
that were directed toward chemoattractants. More recently, it was shown that S1P by 
itself was capable of stimulating, rather than inhibiting, chemotaxis of vascular 
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endothelial cells [10] and mouse embryonic fibroblasts [11]. Thus, S1P appeared to be a 
unique, bimodal regulator of cell migration.  
  In this chapter we describe molecular mechanisms underlying this bimodal regulation 
by S1P, i.e. S1P receptor subtype-specific, positive and negative regulation of cell 
motility and the Rho family GTPases, and S1P regulation of invasion and metastasis of 
malignant melanoma cells via endogenous S1P receptor through the control of Rho 
GTPases.  
 
2. Receptor subtype-specific, bimodal regulation of cell motility and the 
small GTPase Rac by S1P 
After the identification of the S1P-specific Edg family receptors, S1P was found to 
stimulate chemotaxis in vascular endothelial cells via endogenously expressed S1P1 and 
S1P3 [10, 11]. However, it remained unknown how S1P induced inhibition of cell 
migration in several other cell types, although an extracellular mode of this inhibitory 
S1P action was suggested [12]. We showed the activity of each of the S1P receptors on 
cell migration in Boyden chamber assay by employing Chinese hamster ovary (CHO) 
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cells that stably overexpressed each of the widely expressed subtypes, S1P1, S1P2 and 
S1P3. It is known that CHO cells overexpressing exogenous chemoattractant receptors 
can vigorously respond to a concentration gradient of a respective chemoattractant with 
stimulation of directed cell migration in a trans-well migration assay. S1P stimulated 
directed cell migration, i.e. chemotaxis, of either S1P1- or S1P3-expressing CHO cells 
[13, 14]. These two cell types were quite sensitive to S1P with the threshold 
concentrations as low as 0.1-1 nM of S1P. It was also reported that S1P stimulated 
chemotaxis in HEK293 cells overexpressing S1P1 [15]. In sharp contrast, S1P did not 
stimulate trans-well migration of S1P2-expressing cells and vector-transfected control 
cells [13]. However, the addition of a potent chemoattractant insulin-like growth factor 
(IGF-I) unveiled a strong inhibitory effect of S1P on cell migration via S1P2; IGF-I 
stimulated chemotaxis in three S1P receptor subtype-expressing cells and vector control 
cells to comparable degrees. When S1P was present together with IGF-I in the lower 
well of Boyden chamber, IGF-I-directed chemotaxis was completely abolished only in 
S1P2-expressing CHO cells. The S1P2–mediated inhibitory effect of S1P on cell 
migration was potent with the threshold concentration of as low as 1 nM, and was 
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dependent on an S1P concentration gradient. Thus, S1P acts as a chemorepellent. 
  Chemoattractants receptors activate complex, multiple signaling cascades including 
protein tyrosine kinases, lipid kinases and the low molecular weight GTPases [6]. These 
signaling events lead in concert to regulate actin organization and myosin motor 
function, which constitute essential processes for cell migration. Among the low 
molecular weight G proteins, the Rho family GTPases comprise three major members, 
Rho, Rac and Cdc42, and exert distinct regulatory actions on actin cytoskeletons, thus 
playing an important role in cell motility [16 17]; Rho mediates formation of stress 
fibers and focal adhesions, while Rac and Cdc42 direct peripheral actin assembly that 
results in formation of lamellipodia and filopodia, respectively, especially at the leading 
edge of a migrating cell. For example, expression of a dominant negative form of Rac, 
N17-Rac, in a variety of cell types inhibits directed cell migration toward diverse 
chemoattractants, including PDGF, LPA, epidermal growth factor (EGF), insulin and 
colony stimulating factor-1 [16-18], indicating that Rac is required for chemotaxis 
toward these attractants. The expression of dominant negative forms of the Rho family 
GTPases, N17-Rac and N17-Cdc42, but not N19-RhoA, inhibited chemotaxis toward S1P 
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in S1P1- and S1P3-expressing CHO cell types and IGF-I in all the CHO cell types, 
indicating that IGF-I- and S1P-directed chemotaxis was dependent on Rac and Cdc42 
[13]. S1P as well as IGF-I increased an amount in a GTP-bound, active form of Rac in 
S1P1- and S1P3-expressing CHO cells and all the CHO cell types, respectively. In 
S1P2-expressing cells, S1P by itself did not change Rac activity. However, S1P 
dramatically abolished IGF-I-induced Rac activation and lamellipodia formation with a 
dose-response relationship similar to that for S1P inhibition of IGF-I-directed 
chemotaxis [13]. Either S1P or IGF-I did not affect GTP-loading of Cdc42 in any of 
CHO cell types. Rho regulation by S1P and IGF-I was a little complicated; stimulation 
of the attractant receptor S1P1 did not change RhoA activity, but both the repellant 
receptor S1P2 and the attractant S1P3 stimulated RhoA. IGF-I did not affect RhoA or 
Cdc42 activity [13]. Thus, all these data in CHO cells was consistent with the notion 
that stimulation of Rac activity, but not of Cdc42 or RhoA, above the resting level was 
necessary for stimulation of chemotaxis in this cell type. The three Edg family S1P 
receptors transmit overlapping but distinct sets of signals to the Rho family GTPases 
[13, 14, 19, 20], thus allowing receptor subtype-specific, distinct regulatory activities on 
 7 
cell migration (Fig. 1). 
  Chemoattractants that act via G protein-coupled receptors are generally shown to 
mediate chemotaxis and Rac activation via the heterotrimeric Gi protein. However, 
signaling mechanisms of chemorepellant receptors were largely unknown. The 
C-terminal mini-peptide of the heterotrimeric G protein α-subunits (Gα-CTs) serve as 
inhibitors specific for respective G proteins [21]. The expression of either G12α-CT or 
G13α-CT, but not Gsα-CT or Gqα-CT or pertussis toxin, abrogated S1P2 –mediated 
inhibition of Rac and cell migration. Moreover, either S1P2 -G12α or S1P2 -G13α fusion 
receptor [22], but not S1P2 -Gqα fusion receptor, mediated S1P inhibition of Rac and cell 
motility [14]. Our data indicated that the G12/13 family protein coupled S1P2 to 
inhibition of Rac, cell migration and lamellipodia in CHO cells [14]. Furthermore we 
found that downstream of G12/13, Rho mediated S1P2 inhibition of Rac and cell 
migration through a mechanism not involving Rho kinase as a Rho effector [14]. Very 
recently, Sanchez et al. [23] showed that S1P2 mediated inhibition of cell migration 
through stimulating the 3’-phosphatase of phosphoinositides, PTEN, in a Rho 
kinase-dependent manner. This may suggest the possibility that more than a single 
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mechanism could contribute to S1P2 mediated inhibition of cell migration and that the 
mechanism behind S1P2-mediated cell migration inhibition may be different among cell 
types. 
  S1P3 mediated Rac activatin and chemotaxis despite stimulating Rho [13]. We found 
in pertussis toxin-pretreated CHO cells expressing S1P3 that S1P induced inhibition of 
Rac, cell migration and lamellipodia just as in CHO cells expressing S1P2 [14]. Thus, 
inactivation of Gi by pertussis toxin treatment converted S1P3 into the S1P2–like 
repellant receptor. These results indicate that integration of counteracting signals from 
the Gi- and the G12/13-Rho pathways directs either positive or negative regulation of Rac 
and thus cell migration, upon activation of a single S1P receptor isoform.  
 
3. Stimulation and inhibition of melanoma cell invasion and metastasis by 
S1P receptors 
Igarashi and his colleagues [7] first reported that S1P inhibits trans-well migration as 
well as invasion across the Matrigel layer of B16 mouse melanoma cells. They showed 
that S1P immobilized on glass beads exhibited similar inhibitory action on migration of 
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B16 melanoma cells [12]. They also demonstrated the presence of a single class of 
specific, binding site for a radio-labelled S1P on B16 melanoma cells. These 
observations suggested that S1P inhibited melanoma cell migration through an 
extracellular action by specific binding to a cell surface receptor. On the other hand, 
other studies suggested S1P-induced migration inhibition through its intracellular action 
[24]. Our observation that the heterologous expression of S1P2 mediated cell migration 
inhibition in CHO cells prompted us to investigate the possibility that S1P2 receptor 
might mediate migration inhibition of B16 melanoma cells in response to S1P. We 
found that B16 melanoma cells detectably expressed S1P2, but not other S1P receptor 
subtypes [25]. The S1P2-selective antagonist JTE013, which specifically blocks S1P 
binding to S1P2 and prevents Ca2+ mobilization and ERK activation mediated by S1P2, 
completely abolished the inhibitory effect of S1P on B16 cell migration. Thus, B16 
melanoma cell is the example of inhibitory regulation of cell migration by 
endogenously expressed S1P2. 
  In B16 cells, S1P inhibited and stimulated Rac and RhoA, respectively, as in 
S1P2-overexpressing CHO cells, and that both of these responses were totally abrogated 
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by JTE013. S1P did not affect Cdc42 activity. Consistent with the observation in 
S1P2-expressing CHO cells [13], suppression of endogenous Rac activity by 
adenovirus-mediated expression of N17Rac resulted in inhibition of migration of B16 
cells [25]. On the other hand, the inactivation of cellular Rho by C3 toxin reversed S1P 
inhibition of migration in B16 cells. In addition, random migration activity of B16 cell 
in the absence of S1P was also stimulated, rather than inhibited, after C3 toxin 
pretreatment, suggesting that the basal Rho activity is inhibitory for cell migration. This 
latter observation is consistent with a previous report in Rat1 fibroblasts [18]. Similar to 
CHO cells, the Rho kinase inhibitors Y27632 or HA1077, at the concentrations that 
effectively inhibited stress fiber formation, did not reverse S1P inhibition of migration. 
The results indicate that a RhoA effector other than Rho kinase, and cell responses 
different from formation of stress fibers or focal adhesions, are responsible for 
mediating negative regulation of cell motility and invasion by S1P. 
  S1P2 also mediated inhibition of B 16 cell invasion across the Matrigel matrix, which 
is Rac-dependent [25]. With regard to the latter point, it is of note that Rac1 is reported 
to mediate matrix metalloproteinase (MMP)-2 activation in fibrosarcoma cells [26]. 
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Requirement of Rac activity for both cell motility and invasion through extracellular 
matrix has been reported in Rat1 fibroblasts and T lymphoma cells as well [18]. Wang et 
al. [24] showing that S1P inhibited migration of MDA-MB-231 breast carcinoma cells 
which express S1P1 and S1P3 but not S1P2, and postulated that this S1P-inhibitory 
action of tumor cell migration was due to an intracellular action of S1P. It is possible 
that the role for Rac in regulation of migration or invasion might be distinct among cells 
of epithelial and non-epithelial origin through mechanisms involving the regulation of 
cell adhesion molecules. Invasion of B 16 cells was inhibited by N17Rac, like cell 
migration. On the other hand, unlike cell migration, invasion in the absence of S1P was 
inhibited by C3 toxin, suggesting that invasion is dependent upon both Rac and Rho. 
Inhibition of invasion by the expression of N17RhoA, as well as V14RhoA, was reported 
previously in fibroblasts [18]. Despite this, the inhibitory effect of S1P on B16 cell 
invasion was partially reversed by C3 toxin pretreatment, underscoring the role for Rho 
in S1P inhibition of invasion. These composite observations indicate that 
S1P2-mediated Rho stimulation and Rac inhibition are both involved as mechanisms for 
S1P-induced inhibition of B16 cell migration and invasion. However, Rho stimulation 
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by itself doe not appear to be sufficient for migration inhibition in the absence of Rac 
inhibition. This notion is based on the observation obtained in S1P3-overexpressing B16 
cells (see below), in which the addition of S1P together with JTE013 stimulated RhoA 
activity via S1P3, but stimulated, rather than inhibited, Rac activity and migration. Rho 
may be involved in migration and invasion inhibition through negatively regulating Rac, 
as in migration inhibition in CHO cells [14].  
  Metastasis is a temporo-spacially architectured multistep phenomenon that takes 
place in the context of host environment. Rho family GTPases and their extracellular 
regulators were implicated in transformation and invasive phenotypes [18], however, 
their roles in metastasis in vivo were largely unknown. B16 cells that are injected into 
mouse tail veins form multiple metastatic nodules in the lung two or three weeks later. 
We found that daily intraperitoneal injection of S1P reduced the number of metastatic 
nodules [27]. More interestingly, transient treatment of B16 cells with S1P just before 
the tail vein injection also effectively reduced he number of metastatic nodules, 
suggesting that S1P might inhibit very early steps of pulmonary metastasis including 
attachment to the pulmonary capillary endotelium. Adenovirus-mediated transient 
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expression of N17Rac markedly inhibited pulmonary metastasis, suggesting that Rac 
inhibition might underly S1P inhibition of metastasis. The stable overexpression of 
S1P2 augmented S1P-induced cell migration inhibition compared to vector control cells, 
whereas the overexpression of either S1P1 or S1P3 greatly attenuated S1P inhibition of 
migration or stimulated migration. In S1P2–overexpressing cells S1P-induced 
metastasis inhibition was augmented. In contrast, that of either S1P1 or S1P3 resulted in 
aggravation of metastasis in an S1P-dependent manner. These observations suggest that 
Rac is required at a very early stage of hematogenous metastasis before invasion or 
proliferation and that G-protein-coupled receptors could participate in regulation of 
metastasis in receptor subtype-specific ligand-dependent manners.   
 
4. Differential regulation of Rac and cell migration by endogenous Edg 
receptors in vascular smooth muscle and endothelial cells 
As mentioned above, S1P displays unique bimodal activities on two vascular cell types, 
endothelial cells [10, 15] and VSMCs [28]. S1P inhibits VSMC migration, whereas it 
stimulates endothelial cell migration. Both VSMCs and endothelial cells in culture 
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express multiple S1P receptor subtypes. VSMCs express abundant levels of S1P2 and 
S1P3, and endothelial cells express S1P1 and S1P3 [28, 29]. The expression of S1P1 in 
VSMCs and S1P2 in endothelial cells is very faint. The observations, together with the 
fact that S1P1 and S1P3 are chemotactic whereas S1P2 is inhibitory, suggest that the 
vascular cell type-specific, distinct expression pattern of the S1P receptor subtypes can 
account for differential cell motility responses of the two vascular cell types. The S1P 
receptors exerted bimodal regulation on Rac activity in vascular cells; S1P inhibited 
PDGF-induced Rac activation in VSMCs although S1P alone did not affect Rac very 
much, whereas S1P by itself robustly stimulated Rac activity in endothelial cells. The 
overexpression of S1P1 in VSMCs rendered the cells chemotactic toward S1P with 
elevation of Rac, whereas that of S1P2 augmented S1P inhibition of PDGF-directed 
chemotaxis. The overexpression of S1P1 in endothelial cells also made the cells 
repulsive in response to S1P. These observations are consistent with the notion that  
that an integration of the S1P receptor subtype-selective, positive and negative signals 
on cellular Rac activity is a critical determinant for eventual direction of regulation on 
cell motility by S1P.  
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5. Future directions 
The S1P receptors, especially S1P1, S1P2 and S1P3, are expressed widely in a variety of 
tissues during the fetal life as well as the adult life. Both attractive and repulsive signals 
guide migrating cells in tissue remodeling and angiogenesis as well as organogenesis 
and morphogenesis. It is likely that S1P2, a unique negative regulator of Rac, might be 
involved in these pathological and physiological processes in concert with S1P1 and 
S1P3, which are positive regulators of Rac, and presumably also other S1P receptors. It 
would be particularly interesting to see whether these S1P receptors play any role in 
pathological processes such as inflammation, tumor cell progression and atherosclerosis. 
Elucidation of pathological roles for the S1P signaling system is expected to lead to 
development of novel therapeutic strategies including the use of specific antagonists and 
agonists for S1P receptor subtypes and inhibitors of synthesis and degradation of S1P, 
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Figure 1. Bimodal regulation of the Rho family GTPases and cell migration by the 
attractant receptors S1P1 and S1P3, and the repellent receptor S1P2. S1P1 and S1P3 
mediate Rac activation and chemotaxis via Gi. S1P2 mediates Rac inhibition and 
migration inhibition (chemorepulsion), which is mediated by G12/13 and Rho. S1P3 
also stimulates Rho and generates an inhibitory signal for Rac, which is uncovered by 
inactivation of Gi with pertussis toxin. 
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